-+ 0.00%
-+ 0.00%
-+ 0.00%

Wedbush Maintains Neutral on Vor Biopharma, Raises Price Target to $18

Benzinga·05/14/2026 13:19:41
Listen to the news
Wedbush analyst Martin Fan maintains Vor Biopharma (NASDAQ:VOR) with a Neutral and raises the price target from $15 to $18.